Introduction and hypothesisThe aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI).MethodsA systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018.ResultsEight full texts were evaluated but only five were selected for the qualitative and quantitative analyses. Duration of follow-up after Urolastic® injections was significantly heterogeneous, ranging from 6 to 24 months. Secondary injections were needed in 16.7%–35.0% of the treated patients. The pooled proportion of secondary injections was 20% (95% CI: 15%–24%; I2: 0%). Subjective improvement, measured by different means (i.e., patient global impression of improvement PGI-I score) was only assessed by 40% of the selected papers and was > 80% in two cohorts. The objective treatment success was evaluated by four (80.0%) papers and was achieved in all cohorts with a wide proportional range: from 32.7% (i.e., patients without objective SUI symptom cough tests and with a negative pad test) to 67.0%. Its pooled proportion was 57% (95% CI: 38%–75%; I2: 82.3%).ConclusionsUrolastic® showed effectiveness in patients with SUI during a follow-up period of 6–24 months.

中文翻译：

---

Urolastic®，一种用于治疗压力性尿失禁的新型填充剂：系统评价和荟萃分析

介绍和假设本系统评价和荟萃分析的目的是评估注射新填充剂 Urolastic® 治疗压力性尿失禁 (SUI) 患者的有效性和安全性。 Urolastic® 在女性 SUI 患者中的观察和实验研究。三个不同的数据库，Pubmed、Cochrane Central Register of Controlled Trials 和 Scopus，被用来检索从开始到 2018 年 1 月 31 日发表的科学文章。结果 评估了八篇全文，但只选择了五篇进行定性和定量分析。Urolastic® 注射后的随访时间差异很大，从 6 到 24 个月不等。16.7%–35 需要二次注射。0% 接受治疗的患者。二次注射的合并比例为 20%（95% CI：15%–24%；I2：0%）。通过不同方式衡量的主观改善（即患者对改善 PGI-I 评分的总体印象）仅由 40% 的所选论文评估，并且在两个队列中 > 80%。客观治疗成功由四篇 (80.0%) 论文评估，并在所有队列中实现，比例范围很广：从 32.7%（即没有客观 SUI 症状咳嗽测试且垫测试为阴性的患者）到 67.0%。其合并比例为 57%（95% CI：38%–75%；I2：82.3%）。结论 Urolastic® 在 6–24 个月的随访期内对 SUI 患者显示出有效性。患者对改善 PGI-I 评分的总体印象）仅由 40% 的所选论文评估，并且在两个队列中 > 80%。客观治疗成功由四篇 (80.0%) 论文评估，并在所有队列中实现，比例范围很广：从 32.7%（即没有客观 SUI 症状咳嗽测试且垫测试为阴性的患者）到 67.0%。其合并比例为 57%（95% CI：38%–75%；I2：82.3%）。结论 Urolastic® 在 6–24 个月的随访期内对 SUI 患者显示出有效性。患者对改善 PGI-I 评分的总体印象）仅由 40% 的所选论文评估，并且在两个队列中 > 80%。客观治疗成功由四篇 (80.0%) 论文评估，并在所有队列中实现，比例范围很广：从 32.7%（即没有客观 SUI 症状咳嗽测试且垫测试为阴性的患者）到 67.0%。其合并比例为 57%（95% CI：38%–75%；I2：82.3%）。结论 Urolastic® 在 6–24 个月的随访期内对 SUI 患者显示出有效性。没有客观 SUI 症状咳嗽测试且垫测试呈阴性的患者）增加到 67.0%。其合并比例为 57%（95% CI：38%–75%；I2：82.3%）。结论 Urolastic® 在 6–24 个月的随访期内对 SUI 患者显示出有效性。没有客观 SUI 症状咳嗽测试且垫测试呈阴性的患者）增加到 67.0%。其合并比例为 57%（95% CI：38%–75%；I2：82.3%）。结论 Urolastic® 在 6–24 个月的随访期内对 SUI 患者显示出有效性。